New Platforms for Cancer Treatment—Emerging Advances

Dear Colleagues,

The aim of this Special Issue, “New Platforms for Cancer Treatment—Emerging Advances”, is to gather high-quality papers in the field and address pharmaceutical strategies focused on cancer treatment. The alarming rise of cancer cases has become a significant public health concern in recent decades. According to the WHO, ten million people died from cancer alone in 2020, regardless of age or social status. Cancer treatment encompasses various approaches, including surgery, radiotherapy, and conventional chemotherapy, often used in drug combinations. Adverse effects are commonly manifested acutely and chronically.

Nanotechnology has emerged as a more selective option for cancer treatment. It offers targeted therapy, biodistribution, and reduced toxicity. Another strategy for advancing cancer treatment is based on gene therapy, including DNA microRNAs, oncolytic virotherapy, and gene-directed enzyme pro-drug deliveries. Efforts to discover new active molecules or novel combinations continue as a strong branch of cancer treatment novelty. Photodynamic (PDT) and photothermal (PTT) cancer therapies are emerging as new options for the counterpart mutilation of organs and tissues. Monoclonal antibodies in cancer treatment represent a great breakthrough in personalized cancer treatment. These antibodies have been used to target nanostructures loaded with different drugs to tumoral areas in the human body with success.

We encourage researchers from the pharmaceutical and health science disciplines to contribute original and review manuscripts highlighting the latest developments in this field. We welcome manuscripts covering in vitro and in vivo screenings and pre-clinical studies with diverse applications to cancer treatment.

The scope of this Special Issue includes the following:

• Novel drugs or active compounds for cancer treatment;
• Nanostructures applied to cancer treatment;
• Use of photodynamics and photothermal agents in nanotheranostics;
• Targeting approaches to improve selectivity in cancer;
• Biopharmaceutical studies of antitumoral drugs associated with nanodevices;
• Reviews of current and up-to-date research in cancer treatment and new strategies.

Dr. Fernanda Karoline Vieira da Silva Torchelsen
Dr. Maria Alice de Oliveira
Dr. Renata Tupinambá Branquinho
Prof. Dr. Vanessa Carla Furtado Mosqueira
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.